Sagespring Wealth Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$9.5M Buy
10,324
+471
+5% +$478K 0.17% 74
2025
Q4
$10.6M Buy
9,853
+1,768
+22% +$1.69M 0.19% 70
2025
Q3
$6.17M Sell
8,085
-682
-8% -$508K 0.12% 93
2025
Q2
$6.83M Sell
8,767
-622
-7% -$483K 0.15% 83
2025
Q1
$7.75M Buy
9,389
+589
+7% +$490K 0.2% 61
2024
Q4
$6.79M Buy
+8,800
New +$7.29M 0.18% 62

Other funds holding LLY

Sagespring Wealth Partners's LLY Position: Q1 2026 in Review

Sagespring Wealth Partners increased its Eli Lilly (LLY) stake by 4.8% in Q1 2026, buying an estimated $478K and bringing the position to 10,324 shares worth $9.5M. The position accounts for 0.17% of the portfolio, ranked #74.

Sagespring Wealth Partners first reported a position in LLY in Q4 2024 and has held it in 6 quarters since. The position peaked at $10.6M in Q4 2025. 4,355 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Sagespring Wealth Partners held 10,324 shares of Eli Lilly worth $9.5M as of Q1 2026.
  • Sagespring Wealth Partners bought 471 Eli Lilly shares in Q1 2026, an estimated $478K.
  • Eli Lilly made up 0.17% of Sagespring Wealth Partners's portfolio in Q1 2026, its #74 holding.
  • Sagespring Wealth Partners first reported a position in Eli Lilly in Q4 2024 and has held it in 6 quarters since.
  • Sagespring Wealth Partners's Eli Lilly position peaked at $10.6M in Q4 2025.
  • 4,355 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Sagespring Wealth Partners's 13F filing for Q1 2026, filed 7 May 2026.